GSK-626616
| 中文名称 | GSK-626616 |
|---|---|
| 中文同义词 | 化合物GSK-626616;GSK 626616,DYRK抑制剂;(Z)-2-((2,6-二氯苯基)氨基)-5-(喹喔啉-6-基亚甲基)噻唑-4(5H)-酮;化合物GSK-626616,10 MM DMSO 溶液;1025821-33-3;GSK 626616 |
| 英文名称 | GSK-626616 |
| 英文同义词 | (5Z)-2-[(2,6-Dichlorophenyl)amino]-5-(6-quinoxalinylmethylene)-4(5H)-thiazolone;GSK-626616;4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-(6-quinoxalinylmethylene)-, (5Z)-;GSK 626616,DYRK,Inhibitor,Dual specificity tyrosine regulated kinase,GSK-626616,GSK626616,inhibit,Dual specificity tyrosine phosphorylation regulated kinase;(Z)-2-((2,6-Dichlorophenyl)amino)-5-(quinoxalin-6-ylmethylene)thiazol-4(5H)-one;GSK-626616, 10 mM in DMSO;GSK 626616 - Bio-X ? |
| CAS号 | 1025821-33-3 |
| 分子式 | C18H10Cl2N4OS |
| 分子量 | 401.27 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1025821-33-3.mol |
| 结构式 | ![]() |
GSK-626616 性质
| 熔点 | 281 - 282oC |
|---|---|
| 沸点 | 574.8±60.0 °C(Predicted) |
| 密度 | 1.55±0.1 g/cm3(Predicted) |
| 储存条件 | Refrigerator, under inert atmosphere |
| 溶解度 | 可溶于氯仿(轻微,加热),甲醇(轻微) |
| 形态 | 固体 |
| 酸度系数(pKa) | -0.94±0.20(Predicted) |
| 颜色 | 淡黄色至浅黄色 |
| InChI | 1S/C18H10Cl2N4OS/c19-11-2-1-3-12(20)16(11)23-18-24-17(25)15(26-18)9-10-4-5-13-14(8-10)22-7-6-21-13/h1-9H,(H,23,24,25)/b15-9- |
| InChIKey | RJPNRXFBYZVRIB-DHDCSXOGSA-N |
| SMILES | ClC(C=CC=C1Cl)=C1NC2=NC(/C(S2)=C/C3=CC4=C(N=CC=N4)C=C3)=O |
IC50: 0.7 nM (DYRK3)
GSK-626616 abolishes the phosphorylation of S6K1 at Thr389 in nonstimulated HeLa cells. GSK-626616 reduces the phosphorylation of S6K1 at Thr389 in EGF- and insulin-stimulated HeLa cells, showing that mTORC1 activity is impaired.
GSK-626616 (serum-deprived HeLa cells) reduces EGF-induced phosphorylation of PRAS40 at Thr246. Binding of PRAS40 to mTORC1 is enhanced by GSK-626616.
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-105309 | GSK-626616 | 1025821-33-3 | 1 mg | 457元 |
| 2025/12/22 | HY-105309 | GSK-626616 GSK-626616 | 1025821-33-3 | 10mM * 1mLin DMSO | 971元 |
